Jasper Therapeutics confirms that holders of its common stock as of the July 16, 2026 closing date of the Kira Pharmaceuticals acquisition are entitled to one contractual contingent value right (CVR) per share. Each CVR entitles the holder to a pro rata portion of $30 million if the FDA issues a Priority Review Voucher for briquilimab on or before December 31, 2028. The rights are non-transferable and unregistered. Jasper Therapeutics operates in the biotechnology industry.

On July 16, 2026, Jasper Therapeutics, Inc. completed the acquisition of Kira Pharmaceuticals through a merger agreement. The transaction involved the issuance of 5,195,009 shares of voting common stock and 4,644,977 shares of non-voting convertible preferred stock to Kira shareholders. Concurrently, Jasper completed a $132 million private placement (PIPE) involving the sale of approximately 4.7 million shares of preferred stock. The merger includes a contingent value right (CVR) agreement providing an aggregate $30 million milestone payment if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028. Jasper appointed Matthew Ros as Chief Operating Officer and Patrick Crutcher to the Board. Jasper Therapeutics is a biotechnology company developing immunologically-driven therapeutics.

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals and concurrently entered into a $132 million private placement of non-voting convertible preferred stock. The transaction includes an out-licensing deal for KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront and potential milestones. Jasper Therapeutics is a clinical-stage biotechnology company developing biologic agents for immunologically-driven disorders.

Jasper Therapeutics, Inc. received a written notice from Nasdaq indicating that its voting common stock has failed to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. The company has been granted an initial 180-day period, ending November 30, 2026, to regain compliance, with the possibility of an additional 180-day period if other requirements are met. Jasper Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.